Formamidine acetate → 3-[(3-Isopropylisoxazol-5-yl)methyl]-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one
反応式
[NH2:1][C:2]1[C:3](=[O:19])[NH:4][C:5](=[S:18])[N:6]([CH2:9][C:10]2[O:14][N:13]=[C:12]([CH:15]([CH3:17])[CH3:16])[CH:11]=2)[C:7]=1[NH2:8].[C:20](O)(=O)C.C(N)=N>>[CH:15]([C:12]1[CH:11]=[C:10]([CH2:9][N:6]2[C:7]3[N:8]=[CH:20][NH:1][C:2]=3[C:3](=[O:19])[NH:4][C:5]2=[S:18])[O:14][N:13]=1)([CH3:16])[CH3:17]参加物
3
実験手順
The title compound was prepared in accordance with the general method described in Example 12(d) by using 5,6-diamino-1-[(3-isopropylisoxazol-5-yl)methyl]-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (0.070 g, 0.25 mmol, obtained from Example 15(c)) and formamidine acetate (0.040 g, 0.37 mmol) which yielded the title compound (8.0 mg, 11% yield).
後処理
- customThe title compound was prepared in accordance with the general method
出典と根拠
- ORDレコード
- ord-f02a10059ab84c488ff4471655587055
- 出典データセット
- uspto-grants-2011_09
- 特許番号
- US08026244B2
反応ノート
読み込み中…